Form 4: RenovoRx CFO Mark Voll Awarded 80,000 Stock Units

RenovoRx Chief Financial Officer Mark Voll received a grant of 80,000 restricted stock units as compensation for past and future services.

Summary

• Chief Financial Officer Mark Voll was granted 80,000 restricted stock units (RSUs) on April 3, 2026.
• The grant includes 8,777 RSUs for service in February 2026 and 12,270 RSUs for service in March 2026, both of which vested immediately.
• A further 58,953 RSUs were granted for future service, which will vest on a monthly basis.
• Following this transaction, Mark Voll directly owns 117,380 shares of common stock.
• Voll also maintains indirect ownership of 97,200 shares held through the Voll Family Trust.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, as it confirms the CFO's continued commitment to the company and increases insider alignment through equity ownership.

Positives

• CFO direct ownership increased by approximately 213% through this grant.
• A significant portion of executive compensation is tied to equity, aligning management interests with those of shareholders.
• The inclusion of 58,953 RSUs for future service acts as a retention mechanism for key leadership.

Negatives

• The issuance of 80,000 new shares results in minor dilution for existing shareholders.
• The RSUs were granted at a price of $0, representing a pure compensation expense rather than an open-market purchase.

Risks

• Potential for future selling pressure on the stock as the 58,953 RSUs vest monthly and become eligible for sale.
• Heavy reliance on equity-based compensation may suggest a strategy to preserve cash reserves.

Future Outlook

The CFO is scheduled to receive monthly vesting of 58,953 RSUs for future service, with the value of these units determined by the closing price on the last trading day of each respective month.

Management Comments

• The RSUs are valued based on the closing price on the last trading day of the month in which the services were performed.

Industry Context

StockSavvy.ai notes that biotechnology firms frequently utilize equity-heavy compensation packages for C-suite executives to conserve cash for research and development while ensuring management remains focused on long-term share price appreciation.

Comparison to Industry Standards

• The use of RSUs for monthly service is a common practice among micro-cap life sciences companies to manage executive cash compensation.
• The grant size is consistent with industry benchmarks for CFOs in the biotechnology sector, where equity often comprises a substantial portion of total compensation.
• The vesting structure is comparable to peers such as Vericel or CorMedix, which use similar equity incentives for key personnel retention.

Corporate Governance

Related Party Transactions

• The grant of RSUs to an officer of the company constitutes a routine compensation-related transaction between the issuer and a reporting person.

Stakeholder Impact

• Shareholders may experience minor dilution from the eventual conversion of RSUs into common stock.
• The CFO's increased equity stake provides reassurance to investors regarding management's long-term commitment to the company.

Next Steps

• Monthly vesting of 58,953 RSUs for the CFO's future service will continue as scheduled.

Key Dates

Recommendation

The filing reflects routine executive compensation and does not signal a change in fundamental business operations or financial health that would warrant a change in investment rating.

Keywords

RenovoRx, RNXT, Mark Voll, CFO, Insider Trading, Form 4, Restricted Stock Units, Executive Compensation, Biotechnology